Chemomab Therapeutics (CMMB) Cash & Equivalents (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Cash & Equivalents data on file, last reported at $7.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 24.59% year-over-year to $7.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.6 million (up 24.59% YoY), and the FY2025 full-year result was $7.6 million, up 24.59% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $7.6 million, up from $7.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $58.2 million in Q1 2021 and bottomed at $4.7 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $9.6 million (2022), against an average of $15.3 million.
• The widest annual swing landed in 2021, when Cash & Equivalents jumped 457.68%; it then sank 78.23% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $15.2 million in 2021, then slipped by 10.98% to $13.5 million in 2022, then sank by 31.27% to $9.3 million in 2023, then slumped by 34.66% to $6.1 million in 2024, then grew by 24.59% to $7.6 million in 2025.
• The last three Cash & Equivalents figures came in at $7.6 million (Q4 2025), $7.0 million (Q3 2025), and $5.6 million (Q2 2025), per Business Quant data.

Peer Comparison